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Introduction: The aim of this study was to assess cancer incidence in childhood-onset systemic lupus
erythematosus (SLE).
Methods: We ascertained cancers within SLE registries at 10 pediatric centers. Subjects were linked to cancer
registries for the observational interval, spanning 1974 to 2009. The ratio of observed to expected cancers
represents the standardized incidence ratio (SIR) or relative cancer risk in childhood-onset SLE, versus the
general population.
Results: There were 1020 patients aged <18 at cohort entry. Most (82%) were female and Caucasian; mean
age at cohort entry was 12.6 years (standard deviation (SD) = 3.6). Subjects were observed for a total of 7,986
(average 7.8) patient-years. Within this interval, only three invasive cancers were expected. However, 14 invasive
cancers occurred with an SIR of 4.7, 95% confidence interval (CI) 2.6 to 7.8. Three hematologic cancers were found
(two non-Hodgkin’s lymphoma, one leukemia), for an SIR of 5.2 (95% CI 1.1 to 15.2).
The SIRs stratified by age group and sex, were similar across these strata. There was a trend for highest cancer
occurrence 10 to 19 years after SLE diagnosis.
Conclusions: These results suggest an increased cancer risk in pediatric onset SLE versus the general population.
In absolute terms, this represents relatively few events. Of note, risk may be highest only after patients have
transferred to adult care.Introduction
In the past decade, there have been several large studies
elucidating cancer risk in adults with systemic lupus erythe-
matosus (SLE). However, relatively little is known about
cancer risk in childhood-onset SLE. This knowledge gap is
important since pediatric patients have a long disease du-
ration and a heavy burden of severity. Moreover, extrapola-
tions from adult-onset SLE populations are inappropriate,
given the drastic clinical differences (in disease activity,
treatment, organ involvement, and so forth) between
pediatric-onset SLE and adult-onset SLE [1-3].
Our objective was to assess the observed cancer inci-
dence in a large clinical cohort of pediatric-onset SLE
patients. We compared the observed number of cancers* Correspondence: sasha.bernatsky@mcgill.ca
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reproduction in any medium, provided the orover the observation interval with that which would be
expected based on age-specific and sex-specific general
population cancer incidence rates.
Methods
We ascertained cancers within SLE registries at 10
pediatric centers, located in: Birmingham, AL, USA;
Cincinnati, OH, USA; Durham, NC, USA; Hackensack,
NJ, USA; Oklahoma, OK, USA; San Francisco, CA,
USA; Montreal, QC, Canada; Toronto, ON, Canada;
Saskatoon, SK, Canada; and Winnipeg, MB, Canada.
Subjects were linked to state or provincial cancer re-
gistries for the observational interval, spanning 1974
to 2009.
Follow-up was calculated from the date first seen at
the clinic with an SLE diagnosis and the first of three
possible events: death, cancer, or end of study interval
(December 2009). We pooled observed cancers and
person-years of observation. The cancers expected toral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the cohort by the geographically matched age-specific,
sex-specific, and calendar year-specific cancer rates, ob-
tained from the same cancer registries that performed the
cohort linkages. The ratio of observed to expected cancers
represents the standardized incidence ratio (SIR), or the
relative cancer risk in pediatric-onset SLE, versus the
general population. In situ cancers occurring in the SLE
cohort were excluded, since these lesions are generally not
included in general population cancer rates.
We provided estimates for total cancer and for hema-
tological cancers (the most common cancer type, and
the one most often noted in prior case reports). We also
present results stratified by sex, age group, and SLE
duration.
Institutional Review Board ethics approval, including
waiver of informed consent, was provided by the McGill
University Health Centre Institutional Review Board.
Results
There were 1,020 patients aged <18 at cohort entry.
Most patients (82%) were female and Caucasian; the
mean age at cohort entry was 12.6 years (standard de-
viation = 3.6). Subjects were observed for a total of 7,986
(average 7.8) patient-years. Within this observation
interval, only three invasive cancers were expected; how-
ever, 14 invasive cancers occurred (SIR = 4.7, 95% confi-
dence interval (CI) = 2.6, 7.8). The SIRs stratified by age
group and sex were similar across strata (Table 1). There
was a trend for highest cancer occurrence within the
period 10 to 19 years after SLE diagnosis.
At the time of cancer diagnosis, mean SLE duration was
12.3 years (range 2 months, 25.2 years). We performed aTable 1 All observed and expected cancers, along with
standardized incidence ratio and 95% confidence interval
All cancers Observed Expected SIR 95% CI
Stratified by sex
Male 2.0 0.5 4.4 0.5, 16.0
Female 12.0 2.6 4.6 2.4, 8.1
Stratified by age group
0 to 19 years 3.0 0.8 3.9 0.8, 11.4
20+ years 11.0 2.3 4.8 2.4, 8.6
Stratified by SLE duration
< 1 year 2.0 0.1 15.2 1.8, 54.9
1 to 4 years 1.0 0.6 1.8 0.0, 9.9
5 to 9 years 1.0 0.6 1.7 0.0, 9.6
10 to 19 years 8.0 0.9 9.2 4.0, 18.2
20+ years 2.0 0.7 3.1 0.4, 11.1
CI, confidence interval; SIR, standardized incidence ratio; SLE, systemic
lupus erythematosus.sensitivity analysis excluding cancers that occurred within
the first year of SLE diagnosis (since in these cases the
SLE-like manifestations may have actually represented a
paraneoplastic syndrome); here, the overall cancer SIR
was 3.0 (95% CI = 2.3, 7.8).
Three hematologic cancers were found (two non-
Hodgkin’s lymphoma, one leukemia), for an SIR of 5.2
(95% CI = 1.1, 15.2). The ages of the SLE patients (one
male, one female) at lymphoma diagnosis were 16 and
28 years, and the leukemia case was female and diagnosed
at age 7. The leukemia case and one Non-Hodgkin’s
lymphoma were reported within the first year of SLE
diagnosis.
The precision of the CIs was less when the SIRs were
generated by sex strata (hematological cancer SIR for
males = 7.6, 95% CI = 0.2, 42.3; and for females = 4.5,
95% CI = 0.5, 16.2). Similarly wide CIs were seen with
the SIR for hematological cancers for the age group 0 to
19 (SIR = 7.7, 95% CI = 0.9, 27.7) and for the age group
20+ (SIR = 3.2, 95% CI = 0.2, 17.5). The nonhemato-
logical cancers included one cancer each of the bladder,
brain, breast, and thyroid, three head and neck cancers,
and four unspecified cancers. The head and neck malig-
nancy types included one cancer of the lingual tonsil
and the other two were squamous cell carcinomas not
otherwise specified.
Discussion
This study compared the cancer risk in pediatric-onset
SLE patients with age-specific and sex-specific regional
general population cancer rates. These results suggest an
increased cancer risk in pediatric-onset SLE versus the
general population, which appeared to be driven in part
by hematological malignancies. Of course, in absolute
terms, this still translates into relatively few events (1.75
incident cancers per 1,000 person-years), which is some-
what reassuring. A limitation of this study is that pa-
tients may have developed cancer after relocating to
another state or province, thus under-representing the
true cancer incidence in this cohort. Another limitation
is that we are unable to comment on the relative impor-
tance of SLE disease itself, versus therapeutic drugs. We
are also unable to evaluate the effects of race/ethnicity,
or of SLE clinical factors such as type of organ involve-
ment and disease severity.
Our study adds substantially to the pre-existing scant
literature regarding malignancies in pediatric-onset rheu-
matic diseases. There are a few published case reports of
malignancy occurring after the onset of pediatric-onset
SLE [4-6] and these four case reports all document
hematological malignancies: Hodgkin’s lymphoma, mu-
cosa-associated lymphoid tissue lymphoma, Burkitt’s lym-
phoma, and acute lymphoblastic leukemia (ALL). The first
three cases mentioned occurred in teenagers after several
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ALL, occurred in a 6 year old within the first year of
SLE diagnosis. In addition, two additional case reports
document the simultaneous presentation of pediatric-
onset SLE (fulfilling ACR criteria) and ALL, at ages 3
and 7 [7,8].
This possibly suggests a bimodal pattern to hema-
tological malignancies in pediatric-onset SLE. The first
phase of this bimodal pattern would correspond to the
scenario of a young pediatric-onset SLE patient presenting
with pancytopenia, where leukemia (for example, ALL) is
a possible consideration. The second part of this bimodal
pattern of hematological cancer risk in pediatric-onset
SLE seems to be related to lymphoma (both Hodgkin’s
lymphoma and non-Hodgkin’s lymphoma) in older in-
dividuals. Alternatively, the first peak might actually re-
present, at least in part, paraneoplastic presentations
masquerading as pediatric-onset SLE; in either case, clini-
cians should remain vigilant to the possibility of a disease
like ALL in such a setting.
Ours is the first cohort study of the cancer experience
of a large number of patients with pediatric-onset SLE,
comparing the observed number of cancers with those
expected (based on age, sex, and calendar-year appro-
priate rates for the geographically relevant general popu-
lation). In terms of a comparison with what is known in
adults, an increased hematologic cancer risk (especially
Non-Hodgkin’s lymphoma) has also been demonstrated
in adult-onset SLE. Interestingly, in adult-onset SLE the
highest cancer risk, relative to the general population,
occurs in the youngest age group (<45 years) [9].
There is currently also interest in malignancy risk for
other pediatric-onset rheumatic diseases, including ju-
venile idiopathic arthritis. Using similar methods to the
current study, we found rather different results in juven-
ile idiopathic arthritis, for overall cancer, with six cancers
observed and seven expected, leading to an overall SIR
that was not elevated (SIR = 0.8, 95% CI = 0.3, 1.8) [10].
However, all cancers were hematologic, including five
leukemia cases. This potentially represents a signal for a
potentially increased risk of hematological cancer in JIA,
similar to what we present here in pediatric-onset SLE.
The etiology of this potentially increased risk of hema-
tological malignancies in juvenile idiopathic arthritis also
remains to be elucidated.Conclusions
This study represents the most up-to-date results from
our multicenter initiative to clarify baseline cancer risk
in pediatric-onset SLE. There is a possible increased risk
in overall cancer, which may be driven by hematologic
cancer risk. Further work in progress will compare risk
across geography, race/ethnicity, and disease subset.Abbreviations
ALL: Acute lymphoblastic leukemia; CI: Confidence interval; SIR: Standardized
incidence ratio; SLE: Systemic lupus erythematosus.
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